Aadi Bioscience to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically defined cancers, will participate in the Jefferies Global Healthcare Conference in New York from June 8-10, 2022. CEO Neil Desai is set to present during a fireside chat on June 9 at 10am ET. A live webcast will be accessible via the company’s website, with a replay available for 30 days post-event. Aadi is known for its FDA-approved treatment FYARRO for PEComa and has initiated a Phase 2 trial called PRECISION 1 targeting mTOR inhibitor-naïve solid tumors.

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fireside chat at 10am ET on Thursday, June 9, 2022.

A live webcast of the presentation will be available on the “Event Calendar” page within the Investors & News section of the Company’s website at www.aadibio.com. A replay of the webcast will be available for approximately 30 days following the presentation.

About Aadi Bioscience 

Aadi is a biopharmaceutical company focused on precision therapies for genetically defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022 Aadi announced the commercial launch of FYARRO in this indication.

Based on data from Aadi’s Phase 2 registrational study, AMPECT, with FYARRO, and, following discussions with the FDA about other emerging data with FYARRO, Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial in mTOR inhibitor-naïve solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contacts:

Marcy Graham
SVP, Investor Relations & Corporate Communications
Aadi Bioscience
mgraham@aadibio.com

Irina Koffler
LifeSci Advisors LLC
ikoffler@lifesciadvisors.com 

FAQ

What conference will Aadi Bioscience attend in June 2022?

Aadi Bioscience will attend the Jefferies Global Healthcare Conference from June 8-10, 2022.

When is Neil Desai's presentation at the Jefferies Conference?

Neil Desai's presentation is scheduled for June 9, 2022, at 10am ET.

How can I watch Aadi Bioscience's presentation?

You can watch the presentation live on Aadi Bioscience's website under the Investors & News section.

What is FYARRO and its significance for Aadi Bioscience?

FYARRO is Aadi Bioscience's FDA-approved treatment for PEComa, highlighting the company's focus on precision therapies.

What is the PRECISION 1 trial initiated by Aadi Bioscience?

The PRECISION 1 trial is a Phase 2 study targeting mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 alterations.